AU1043201A - Cyclosporin formulation - Google Patents

Cyclosporin formulation

Info

Publication number
AU1043201A
AU1043201A AU10432/01A AU1043201A AU1043201A AU 1043201 A AU1043201 A AU 1043201A AU 10432/01 A AU10432/01 A AU 10432/01A AU 1043201 A AU1043201 A AU 1043201A AU 1043201 A AU1043201 A AU 1043201A
Authority
AU
Australia
Prior art keywords
cyclosporin formulation
cyclosporin
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU10432/01A
Other languages
English (en)
Inventor
Geena Malhotra
Vinay G. Nayak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cipla Ltd
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IN1999/000062 external-priority patent/WO2001032143A1/fr
Priority claimed from GB0012816A external-priority patent/GB2362573A/en
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of AU1043201A publication Critical patent/AU1043201A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU10432/01A 1999-11-02 2000-10-27 Cyclosporin formulation Abandoned AU1043201A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
WOIN99/00062 1999-11-02
PCT/IN1999/000062 WO2001032143A1 (fr) 1999-11-02 1999-11-02 Composition pharmaceutique pour administer des substances actives sur le plan pharmaceutique insolubles dans l'eau et procede de preparation afferent
GB0012816A GB2362573A (en) 2000-05-25 2000-05-25 Cyclosporin formulation
GB0012816 2000-05-25
PCT/GB2000/004143 WO2001032142A1 (fr) 1999-11-02 2000-10-27 Formulation de cyclosporine

Publications (1)

Publication Number Publication Date
AU1043201A true AU1043201A (en) 2001-05-14

Family

ID=26244360

Family Applications (1)

Application Number Title Priority Date Filing Date
AU10432/01A Abandoned AU1043201A (en) 1999-11-02 2000-10-27 Cyclosporin formulation

Country Status (3)

Country Link
EP (1) EP1227793A1 (fr)
AU (1) AU1043201A (fr)
WO (1) WO2001032142A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
GB2391471B (en) * 2002-08-02 2005-05-04 Satishchandra Punambhai Patel Pharmaceutical compositions
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
FR2873923B1 (fr) * 2004-08-05 2007-01-12 Gattefosse Holding Sa Particule solide anhydre contenant une composition lipidique liquide et composition pharmaceutique contenant lesdites particules
US20090169583A1 (en) * 2005-02-08 2009-07-02 Pfizer, Inc. Solid Adsorbates of Hydrophobic Drugs
US7501393B2 (en) 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US7745400B2 (en) 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
US9114071B2 (en) 2007-04-04 2015-08-25 Sigmoid Pharma Limited Oral pharmaceutical composition
ES2528421T3 (es) * 2008-10-22 2015-02-09 Santen Pharmaceutical Co., Ltd Composición farmacéutica de mejor absorción a través del tracto intestinal
ES2649112T3 (es) 2009-05-18 2018-01-10 Sigmoid Pharma Limited Composición que comprende gotas de aceite
WO2011018504A2 (fr) 2009-08-12 2011-02-17 Sigmoid Pharma Limited Compositions immunomodulatrices comprenant une matrice polymère et une phase huileuse
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
BR112017009510A2 (pt) 2014-11-07 2017-12-19 Sigmoid Pharma Ltd composições compreendendo ciclosporina

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
KR0146671B1 (ko) * 1994-02-25 1998-08-17 김충환 사이클로스포린-함유 분말 조성물
EP0760237A1 (fr) * 1995-08-30 1997-03-05 Cipla Limited Microémulsions huile-dans-l'eau
CA2283780A1 (fr) * 1997-03-12 1998-09-17 Abbott Laboratories Systemes lipophiles binaires permettant l'administration de composes lipophiles
ID25908A (id) * 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida

Also Published As

Publication number Publication date
EP1227793A1 (fr) 2002-08-07
WO2001032142A1 (fr) 2001-05-10

Similar Documents

Publication Publication Date Title
AU3243300A (en) Multiparticulate formulation
AUPP970099A0 (en) Concrete formulation
AU7998900A (en) Automotive-ceiling-mounted monitor
AU1173201A (en) Skin-gripper
EG24226A (en) Formulation
AU4328800A (en) Pharmaceutical formulation
AU1043201A (en) Cyclosporin formulation
AUPQ147699A0 (en) Sunscreen formulations
AU2792700A (en) Pharmaceutical composition containing cyclosporin
GB9905898D0 (en) Controlled-dose formulation
GB9902304D0 (en) Formulation
AU2804600A (en) Arylaminoalkylamides
AU3303300A (en) Cleaning formulation
AU2699800A (en) Organoceramics
AU3191100A (en) Ligand-bonded complex
AU3839900A (en) Pharmaceutical formulation
AU4081300A (en) Centroid integration
AU3930399A (en) Cyclosporin preparations
GB9927614D0 (en) Sterliant formulation
AU1901801A (en) Glucofuranoses
AU1388501A (en) Pharmaceutical formulation
AU1915601A (en) Periotome
AU2582200A (en) Windturbine
AU2197301A (en) Microlamp
AU3175500A (en) Insecticide formulation

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase